Results 11 to 20 of about 160,832 (337)
Cell Death and Disease, 2021 The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun +5 more
doaj +1 more source
A bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer [PDF]
, 2014 © 2014 Chan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited ...
AJ Sutton +36 more
core +9 more sources
Pharmacogenomics and gemcitabine
Annals of Oncology, 2006 Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to cisplatin-based chemotherapy of 11 months. No predictive factor of response to cisplatin-based chemotherapy is yet available in clinical practice.
R, Rosell +4 more
openaire +2 more sources
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. [PDF]
, 2014 BackgroundPancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have ...
Bold, Richard J +3 more
core +2 more sources
Journal of Pharmacological Sciences, 2015 Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami +16 more
doaj +1 more source
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. [PDF]
, 2016 Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic
Chen, Qiu-Dan +8 more
core +2 more sources
Molecular Cancer, 2022 Background Although gemcitabine has been considered as the first-line drug for advanced pancreatic cancer (PC), development of resistance to gemcitabine severely limits the effectiveness of this chemotherapy, and the underlying mechanism of gemcitabine ...
Jianyou Gu +12 more
doaj +1 more source
Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation. [PDF]
PLoS ONE, 2010 Gemcitabine is a cytotoxic cytidine analog, which is widely used in anti-cancer therapy. One mechanism by which gemcitabine acts is by inhibiting nucleotide excision repair (NER).
Andrea Schäfer +4 more
doaj +1 more source
Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]
, 2003 Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core +1 more source
Journal of Pancreatology, 2021 . Objective:. Pancreatic cancer (PC) is an aggressive cancer with ineffective treatment. Inhibition of stearoyl-CoA desaturase 1 (SCD1) suppresses cancer proliferation and might act as a novel chemotherapy supplement, but this has not been investigated ...
Amon B. Hackney +4 more
doaj +1 more source